BCRX
BioCryst Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26
Figures on this page computed 2026-11-07 11:24 UTC
Last close
7.63USD
Market data, 2026-11-05
Weekly closes, 2025-11-07 to 2026-11-05
Over that span: +7.6%
Except where said otherwise: 10-K for 2025, filed 2026-02-26
6.1xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
30.2%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
39.4%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- USD
- computed
Safety is the furthest below its sector's middle: 0.49 against 0.53 on the market's range.
- Growth117.9%97 of 100, above its sector
- Returns on capital51.3%100 of 100, above its sector
- Margins97.8%96 of 100, above its sector
- Price6.1x71 of 100, above its sector
- Safety2.0649 of 100, below its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Five bars, one line
lens 7 of 9Each against its own average
5 of 5 readExcept where said otherwise: 10-K for 2025, filed 2026-02-26
- Sales3.93x
Its own average over 10 years, 222.4M.
- Profit-2.65x
Its own average over 10 years, -99.7M.
- Free cash flow-6.48x
Its own average over 10 years, -53.2M.
- Debt0.09x
Its own average over 10 years, 125.3M.
- Price0.98x
Its own average over 11 years, 8. Market data, 2026-11-05
Free cash flow is furthest from its own average, at -6.48 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Shares in issue |
|---|---|---|
| 2016-12-31 | 100.0 | 100.0 |
| 2017-12-31 | 95.6 | 114.6 |
| 2018-12-31 | 78.4 | 140.0 |
| 2019-12-31 | 185.3 | 156.9 |
| 2020-12-31 | 67.6 | 227.0 |
| 2021-12-31 | 596.4 | 243.0 |
| 2022-12-31 | 1,027.7 | 252.3 |
| 2023-12-31 | 1,257.6 | 260.8 |
| 2024-12-31 | 1,710.3 | 280.5 |
| 2025-12-31 | 3,319.7 | 296.6 |
How sales was got
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
How shares in issue was got
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
Figures behind the shape
Growth
117.9%faster is higher, placed against 4,950 companies as of 2026-11-06
Five-year revenue growth rate117.9%
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- USD
- computed
One-year change in net income396.9%
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- USD
- computed
Returns on capital
51.3%higher is higher, placed against 5,089 companies as of 2026-11-06
Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
Return on equityn/mnegative equity
Negative equity.
Net Income / Shareholders' Equity x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
Return on assets51.3%
Net Income / Total Assets x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
Margins
97.8%wider is higher, placed against 3,412 companies as of 2026-11-06
Gross margin97.8%
Gross Profit / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
Operating margin39.0%
Operating Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
Net margin30.2%
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
Free cash flow margin39.4%
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
Price
6.1xcheaper is higher, placed against 4,362 companies as of 2026-11-06
Price to earnings6.1x
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
Price to bookn/a10-Q for 2025, filed 2026-11-04
We do not hold this figure for this company, so there is nothing to place.
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-070112
- Reported in
- USD
- computed
- 10-Q for 2025, filed 2026-11-04
- computed
- 10-K for 2025, filed 2026-02-26
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
- 10-K for 2025, filed 2026-02-26
Price to sales ratio1.9x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
Safety
2.06safer is higher, placed against 3,227 companies as of 2026-11-06
Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-04
Current ratio2.0610-Q for 2025, filed 2026-11-04
Current Assets / Current Liabilities
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-070112
- Reported in
- USD
- 10-Q for 2025, filed 2026-11-04
- 10-Q for 2025, filed 2026-11-04
Interest coverage4.3x
Operating Income / Interest Expense
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
Altman Z-Score1.87
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- USD
- Computed from the 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26
What it pays out
n/aWe do not hold this figure for this company, so there is nothing to place.
more, and better covered, is higher, with no cohort held
Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012240
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-06
- Reported in
- USD
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.